Tiotropium Br/Olodaterol Hcl
Brand name: Stiolto Respimat
Rank #129 of 500 drugs by total cost
$130.3M
Total Cost
201,233
Total Claims
$130.3M
Total Cost
6,443
Prescribers
$648
Cost per Claim
27,590
Beneficiaries
275,538
30-Day Fills
$20K
Avg Cost/Provider
31
Avg Claims/Provider
About Tiotropium Br/Olodaterol Hcl
Tiotropium Br/Olodaterol Hcl (sold as Stiolto Respimat) was prescribed 201,233 times by 6,443 Medicare Part D providers in 2023, costing the program $130.3M. At $648 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 126 | Cenegermin-Bkbj (Oxervate) | $133.5M | 3,601 |
| 127 | Teriflunomide (Aubagio) | $131.9M | 18,010 |
| 128 | Umeclidinium Bromide (Incruse Ellipta) | $131.6M | 290,677 |
| 129 | Tiotropium Br/Olodaterol Hcl (Stiolto Respimat) | $130.3M | 201,233 |
| 130 | Immun Globg(Igg)/Malt/Iga Ov50 (Octagam) | $129.5M | 9,657 |
| 131 | Pregabalin (Pregabalin) | $124.3M | 2,696,923 |
| 132 | Dronedarone Hcl (Multaq) | $123.4M | 98,156 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology